These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36490302)

  • 21. First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China.
    Yang R; Wu R; Sun J; Sun F; Rupon J; Huard F; Korth-Bradley JM; Xu L; Luo B; Liu YC; Rendo P
    Medicine (Baltimore); 2021 May; 100(21):e26077. PubMed ID: 34032739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene therapy for hemophilia.
    Nathwani AC
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):569-578. PubMed ID: 36485127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valoctocogene Roxaparvovec and Etranacogene Dezaparavovec: Novel Gene Therapies for Hemophilia A and B.
    Dougherty JA; Dougherty KM
    Ann Pharmacother; 2024 Aug; 58(8):834-848. PubMed ID: 37978816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.
    Nathwani AC; Tuddenham EG; Rangarajan S; Rosales C; McIntosh J; Linch DC; Chowdary P; Riddell A; Pie AJ; Harrington C; O'Beirne J; Smith K; Pasi J; Glader B; Rustagi P; Ng CY; Kay MA; Zhou J; Spence Y; Morton CL; Allay J; Coleman J; Sleep S; Cunningham JM; Srivastava D; Basner-Tschakarjan E; Mingozzi F; High KA; Gray JT; Reiss UM; Nienhuis AW; Davidoff AM
    N Engl J Med; 2011 Dec; 365(25):2357-65. PubMed ID: 22149959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practical Implications of Factor IX Gene Transfer for Individuals with Hemophilia B: A Clinical Perspective.
    Miesbach W; Sawyer EK
    Hum Gene Ther Clin Dev; 2018 Jun; 29(2):80-89. PubMed ID: 29624465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced Factor IX Activity following Administration of AAV5-R338L "Padua" Factor IX versus AAV5 WT Human Factor IX in NHPs.
    Spronck EA; Liu YP; Lubelski J; Ehlert E; Gielen S; Montenegro-Miranda P; de Haan M; Nijmeijer B; Ferreira V; Petry H; van Deventer SJ
    Mol Ther Methods Clin Dev; 2019 Dec; 15():221-231. PubMed ID: 31709273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.
    Crudele JM; Finn JD; Siner JI; Martin NB; Niemeyer GP; Zhou S; Mingozzi F; Lothrop CD; Arruda VR
    Blood; 2015 Mar; 125(10):1553-61. PubMed ID: 25568350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety and efficacy of factor IX gene therapy in hemophilia B.
    Nathwani AC; Reiss UM; Tuddenham EG; Rosales C; Chowdary P; McIntosh J; Della Peruta M; Lheriteau E; Patel N; Raj D; Riddell A; Pie J; Rangarajan S; Bevan D; Recht M; Shen YM; Halka KG; Basner-Tschakarjan E; Mingozzi F; High KA; Allay J; Kay MA; Ng CY; Zhou J; Cancio M; Morton CL; Gray JT; Srivastava D; Nienhuis AW; Davidoff AM
    N Engl J Med; 2014 Nov; 371(21):1994-2004. PubMed ID: 25409372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
    Ozelo MC; Mahlangu J; Pasi KJ; Giermasz A; Leavitt AD; Laffan M; Symington E; Quon DV; Wang JD; Peerlinck K; Pipe SW; Madan B; Key NS; Pierce GF; O'Mahony B; Kaczmarek R; Henshaw J; Lawal A; Jayaram K; Huang M; Yang X; Wong WY; Kim B;
    N Engl J Med; 2022 Mar; 386(11):1013-1025. PubMed ID: 35294811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
    Korth-Bradley JM; Rendo P; Smith L; Altisent C
    Clin Ther; 2016 Apr; 38(4):936-44. PubMed ID: 26969334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.
    Chowdary P; Shapiro S; Makris M; Evans G; Boyce S; Talks K; Dolan G; Reiss U; Phillips M; Riddell A; Peralta MR; Quaye M; Patch DW; Tuddenham E; Dane A; Watissée M; Long A; Nathwani A
    N Engl J Med; 2022 Jul; 387(3):237-247. PubMed ID: 35857660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
    Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
    Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX-knockout mice.
    Wang L; Yang Y; Breton CA; White J; Zhang J; Che Y; Saveliev A; McMenamin D; He Z; Latshaw C; Li M; Wilson JM
    Blood; 2019 Jun; 133(26):2745-2752. PubMed ID: 30975639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.
    Kavakli K; Smith L; Kuliczkowski K; Korth-Bradley J; You CW; Fuiman J; Zupančić-Šalek S; Abdul Karim F; Rendo P
    Haemophilia; 2016 May; 22(3):381-8. PubMed ID: 26823276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua.
    Nair N; De Wolf D; Nguyen PA; Pham QH; Samara-Kuko E; Landau J; Blouse GE; Chuah MK; VandenDriessche T
    Blood; 2021 May; 137(21):2902-2906. PubMed ID: 33735915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy.
    Nair N; Rincon MY; Evens H; Sarcar S; Dastidar S; Samara-Kuko E; Ghandeharian O; Man Viecelli H; Thöny B; De Bleser P; VandenDriessche T; Chuah MK
    Blood; 2014 May; 123(20):3195-9. PubMed ID: 24637359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.
    Zhang R; Wang Q; Zhang L; Chen S
    Front Med; 2015 Mar; 9(1):90-9. PubMed ID: 25663062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.
    Finn JD; Nichols TC; Svoronos N; Merricks EP; Bellenger DA; Zhou S; Simioni P; High KA; Arruda VR
    Blood; 2012 Nov; 120(23):4521-3. PubMed ID: 22919027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.
    Sun J; Hakobyan N; Valentino LA; Feldman BL; Samulski RJ; Monahan PE
    Blood; 2008 Dec; 112(12):4532-41. PubMed ID: 18716130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.
    Rangarajan S; Walsh L; Lester W; Perry D; Madan B; Laffan M; Yu H; Vettermann C; Pierce GF; Wong WY; Pasi KJ
    N Engl J Med; 2017 Dec; 377(26):2519-2530. PubMed ID: 29224506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.